BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11425235)

  • 1. Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line.
    Lichtenfels R; Ackermann A; Kellner R; Seliger B
    Electrophoresis; 2001 May; 22(9):1801-9. PubMed ID: 11425235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
    Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
    J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
    Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression].
    Wu XX; Mizutani Y; Kakehi Y; Nakamura E; Mitsumori K; Takahashi T; Terachi T; Okada Y; Yoshida O
    Hinyokika Kiyo; 1998 Sep; 44(9):621-6. PubMed ID: 9805665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
    Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
    Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping and identification of interferon gamma-regulated HeLa cell proteins separated by immobilized pH gradient two-dimensional gel electrophoresis.
    Shaw AC; Røssel Larsen M; Roepstorff P; Justesen J; Christiansen G; Birkelund S
    Electrophoresis; 1999; 20(4-5):984-93. PubMed ID: 10344276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
    Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
    Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
    Raffaghello L; Nozza P; Morandi F; Camoriano M; Wang X; Garrè ML; Cama A; Basso G; Ferrone S; Gambini C; Pistoia V
    Cancer Res; 2007 Jun; 67(11):5471-8. PubMed ID: 17545629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential protein profiling in renal-cell carcinoma.
    Shi T; Dong F; Liou LS; Duan ZH; Novick AC; DiDonato JA
    Mol Carcinog; 2004 May; 40(1):47-61. PubMed ID: 15108329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
    Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
    Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma.
    Unwin RD; Harnden P; Pappin D; Rahman D; Whelan P; Craven RA; Selby PJ; Banks RE
    Proteomics; 2003 Jan; 3(1):45-55. PubMed ID: 12548633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immobilized pH gradient two-dimensional gel electrophoresis and mass spectrometric identification of cytokine-regulated proteins in ME-180 cervical carcinoma cells.
    Matsui NM; Smith DM; Clauser KR; Fichmann J; Andrews LE; Sullivan CM; Burlingame AL; Epstein LB
    Electrophoresis; 1997; 18(3-4):409-17. PubMed ID: 9150919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of HLA-G expression in renal cell carcinoma.
    Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
    Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [2-DE profiling and differential analysis of human bronchial epithelial tissues in different stages of carcinogenesis].
    Wu XY; Li C; Xiao ZQ; Li JL; Feng XP; Yi H; Li MY; Chen ZC
    Ai Zheng; 2004 May; 23(5):522-30. PubMed ID: 15142447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
    Falk CS; Noessner E; Weiss EH; Schendel DJ
    Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.